Comparing Safety Across the Class: Tolerability Trade-offs and Durability of Response

This episode, titled "Comparing Safety Across the Class: Tolerability Trade-offs and Durability of Response," featured panelists discussing the following critical questions:

Safety and tolerability differences across these five agents are clinically meaningful and directly affect adherence and total cost of care. How do clinicians weigh tolerability profiles, such as weight gain, akathisia, sedation, metabolic effects, and tardive dyskinesia risk, when selecting among the adjunctive options?

Long-term data and real-world evidence are limited across all agents in this class. What do we know about durability of response with adjunctive antipsychotics in major depressive disorder (MDD), and what are the evidence gaps that matter most for clinical decision-making?

Led by the moderator, the expert mental health experts examined network meta-analysis data comparing weight gain and akathisia across the five agents, with Rhee noting lumateperone did not differ from placebo on weight gain while the other four agents showed increased risk, and cautioning that these exploratory findings warrant careful interpretation given limited clinical data. Bhide added a payer perspective, sharing that her organization removed prior step-therapy requirements for newer atypical antipsychotics after reviewing utilization evidence, leaving copay differentials as the primary distinguishing factor among options today. Thase then addressed the long-term evidence gap, explaining that FDA relapse-prevention data requirements have historically applied to antidepressants but not to adjunctive atypical antipsychotics despite long-term risks like weight gain and tardive dyskinesia, and described a nuanced, iterative approach to attempting dose reduction or discontinuation after sustained response.

Throughout the conversation, the experts provided a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

In the next episode, "Matching Patient to Medication: Final Perspectives on Adjunctive Antipsychotic Therapy in MDD," panelists continue their discussion on major depressive disorder and highlight the patient-level factors — including weight status, sleep disturbance, and medication sensitivity — that guide treatment selection, closing with final reflections from the panel.